Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Antisense Therapeutics Ltd.

Latest From Antisense Therapeutics Ltd.

PIPELINE WATCH: Six Approvals, Eight Filings And One Launch

This week's Pipeline Watch, a snapshot of all the late-stage R&D and regulatory events in the pharma and biotech industries, is now available to view.

Pipeline Watch Approvals

Chiasma Looks Ahead To First Approval With "Revolutionary" Technology Opportunity

Anticipating an April 15 user fee date for oral ocreotide for acromegaly, Chiasma thinks its platform technology to make peptides orally available can offer substantial opportunities for therapeutic optionality.

BioPharmaceutical United States

FINANCE ROUNDUP: Venture Cash Flows To Biotech, IPOs Stagnate

A surprising slide in global stock indices on Monday did not stop venture capital investors from keeping their commitments to private biotechnology companies during the last full week of August, but no new initial public offerings launched in the US between Aug. 24 and 28.

Metabolic Disorders Infectious Diseases

Deals Shaping The Medical Industry, June 2015

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in May 2015.

BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Neurology, Nervous System
  • Ophthalmic
  • Respiratory, Pulmonary
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Australia
  • Parent & Subsidiaries
  • Antisense Therapeutics Ltd.
  • Senior Management
  • Phillip Hains, CFO
    George Tachas, PhD, Dir., Drug Discovery & Patents
  • Contact Info
  • Antisense Therapeutics Ltd.
    Phone: (61) 3 9827 8999
    10 Wallace Ave.
    Level 1
    Toorak, 3142